ATE359809T1 - Gefriergetrocknete hgf-präparationen - Google Patents

Gefriergetrocknete hgf-präparationen

Info

Publication number
ATE359809T1
ATE359809T1 AT00935503T AT00935503T ATE359809T1 AT E359809 T1 ATE359809 T1 AT E359809T1 AT 00935503 T AT00935503 T AT 00935503T AT 00935503 T AT00935503 T AT 00935503T AT E359809 T1 ATE359809 T1 AT E359809T1
Authority
AT
Austria
Prior art keywords
freeze
growth factor
hepatocyte growth
aqueous solution
solution containing
Prior art date
Application number
AT00935503T
Other languages
English (en)
Inventor
M Chiba
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Application granted granted Critical
Publication of ATE359809T1 publication Critical patent/ATE359809T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT00935503T 1999-05-31 2000-05-31 Gefriergetrocknete hgf-präparationen ATE359809T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP15176999 1999-05-31

Publications (1)

Publication Number Publication Date
ATE359809T1 true ATE359809T1 (de) 2007-05-15

Family

ID=15525900

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00935503T ATE359809T1 (de) 1999-05-31 2000-05-31 Gefriergetrocknete hgf-präparationen

Country Status (11)

Country Link
EP (1) EP1180368B1 (de)
JP (1) JP4635340B2 (de)
KR (1) KR100767473B1 (de)
CN (1) CN100448482C (de)
AT (1) ATE359809T1 (de)
AU (1) AU5103200A (de)
CA (1) CA2375779A1 (de)
DE (1) DE60034445T2 (de)
ES (1) ES2408784T3 (de)
HK (1) HK1044471A1 (de)
WO (1) WO2000072873A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
RU2329823C2 (ru) * 2002-10-29 2008-07-27 Алза Корпорейшн Стабилизированные твердые полипептидные частицы
CN100345590C (zh) * 2003-08-14 2007-10-31 福建广生堂药业有限公司 包含促肝细胞生长素和干扰素的口含片
JP5653572B2 (ja) * 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
KR20070008645A (ko) 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
CN100464735C (zh) * 2006-08-02 2009-03-04 沈阳斯佳科技发展有限公司 促肝细胞生长素水针制剂的制备方法
CN100525833C (zh) * 2007-09-21 2009-08-12 南京大学 右旋糖苷40/多肽冻干粉针剂成型的方法
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN101670092B (zh) * 2009-09-01 2012-02-08 广东隆赋药业有限公司 一种注射用促肝细胞生长素冻干粉针剂的制备方法
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
HRP20161703T1 (hr) * 2012-11-20 2017-03-10 Fresenius Kabi Usa, Llc Formulacije kaspofungin acetata
CN106456695B (zh) * 2014-04-28 2019-11-12 卫材R&D管理有限公司 Hgf的冻干配制品
CN104013974A (zh) * 2014-06-11 2014-09-03 中国人民解放军军事医学科学院放射与辐射医学研究所 肝细胞生长因子基因在制备用于预防和/或治疗疼痛药物中的应用
WO2016039163A1 (ja) * 2014-09-10 2016-03-17 クリングルファーマ株式会社 神経疾患の治療に適したｈｇｆ製剤
CN105521483A (zh) * 2014-09-30 2016-04-27 陕西艾美雅生物科技有限公司 复合生物活性因子的冻干方法及冻干粉
KR20170079409A (ko) * 2015-12-30 2017-07-10 한미약품 주식회사 지속형 인간 성장 호르몬 결합체의 신규 액상 제제
KR102275262B1 (ko) 2016-03-17 2021-07-12 에자이 알앤드디 매니지먼트 가부시키가이샤 활성 간세포 성장 인자(hgf)를 생성하는 방법
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
EP4574211A3 (de) 2021-05-14 2025-09-10 Claris Biotherapeutics, Inc. Zusammensetzungen von wachstumsfaktor zur behandlung von augenerkrankungen
CN116298244B (zh) * 2023-02-08 2025-10-10 安徽大千生物工程有限公司 一种总抗氧化物状态测定试剂盒及其制备、使用方法
CN120713840B (zh) * 2025-03-26 2025-11-25 天士力医药集团股份有限公司 一种PEG-hmFGF-21注射液及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200069A (nl) * 1982-01-11 1983-08-01 Philips Nv Weergeefinrichting met vloeibaar kristal.
JPH03505334A (ja) * 1989-04-11 1991-11-21 イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド 凍結乾燥されたペプチド製剤
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
JP3697460B2 (ja) * 1992-07-17 2005-09-21 敏一 中村 Ｈｇｆ含有製剤
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren

Also Published As

Publication number Publication date
JP4635340B2 (ja) 2011-02-23
CN1367703A (zh) 2002-09-04
DE60034445D1 (de) 2007-05-31
ES2408784T3 (es) 2013-06-21
HK1044471A1 (en) 2002-10-25
WO2000072873A1 (fr) 2000-12-07
EP1180368B1 (de) 2007-04-18
CA2375779A1 (en) 2000-12-07
KR20020064141A (ko) 2002-08-07
CN100448482C (zh) 2009-01-07
AU5103200A (en) 2000-12-18
DE60034445T2 (de) 2008-01-03
EP1180368A1 (de) 2002-02-20
EP1180368A4 (de) 2004-03-24
KR100767473B1 (ko) 2007-10-17

Similar Documents

Publication Publication Date Title
DE60034445D1 (de) Gefriergetrocknete hgf-präparationen
ES2263450T3 (es) Preparaciones de g-csf estabilizadas a largo plazo.
DE69531314D1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
CA2226548A1 (en) Lyophilized hepatocyte growth factor preparations
KR920019371A (ko) 안정화된 인자 ⅷ 제제
FI903440A0 (fi) Stabiliserade fgf-sammansaettningar och foerfarande foer deras framstaellning.
PT1121144E (pt) Preparados de insulina concentrada estavel para administracao pulmonar
PT86810B (pt) Processo para a preparacao de complexos estaveis de interferao
EP1260230A1 (de) Langfristig stabilisierte präparate
JP2002332234A (ja) ボリコナゾールを含有する薬剤製剤
ATE203411T1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
AU5909498A (en) Formulations for amylin agonist peptides
ES2224917T1 (es) Composiciones farmaceuticas de agente fibrinolitico.
DK0490549T3 (da) Stabilisering af calcitonin-holdige farmaceutiske præparater
DK0973546T3 (da) Stabiliserede formuleringer med human papillomavirus
RU2004133349A (ru) Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата
DE60117248D1 (de) Parenterale lösung enthaltend amiodaron
KR880001154B1 (ko) 항생물질의 안정화 방법
EP0612530A3 (de) Einen für Tumore cytotoxischen Faktor enthaltende pharmazeutische Zusammensetzung.
NO911119D0 (no) Fremgangsmaate for fremstilling av farmasoeytisk jodpreparat
KR910005886A (ko) 안정화 백혈구 인터페론
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
ATE332133T1 (de) Pharmazeutische zusammensetzung enthaltend glyzin als stabilisator
DE69112028D1 (de) Arzneizusammensetzungen zur rektalen Verabreichung enthaltend gefriergetrocknetes Calcitonin.
DE68902755D1 (de) Antineoplastische formulierungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties